Literature DB >> 32749611

Somatic DNA copy number alterations in non-dysplastic Barrett's esophagus.

Zachary M Callahan1, Wennuan Liu2, Jun Hou2, S Lilly Zheng2, Jamaal Rehman3, H Mason Hedberg4, Craig S Brown4, Bailey Su4, Mikhail Attaar4, Kristine Kuchta5, MaryAnn Regner3, JoAnn Carbray4, Jianfeng Xu2, Michael Ujiki4.   

Abstract

BACKGROUND: The purpose of this study was to analyze non-dysplastic Barrett's esophagus (NDBE) biopsy tissue and compare the rate of somatic DNA copy number alterations (CNAs) in patients who subsequently progressed to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) to those patients who did not.
METHODS: A retrospectively collected database of Barrett's esophagus (BE) patients spanning a 16-year period was queried. Patients who progressed from NDBE to HGD or EAC were identified and compared to patients who did not. Initial biopsy specimens were microdissected and extracted DNA underwent Multiplex Ligation-dependent Probe Amplification (MLPA) for CNAs. Comparisons between progressors and non-progressors were made with Fisher's exact and two-sample t tests. Logistic regression assessed factors associated with progression.
RESULTS: Of the 2459 patients in the BE database, 36 patients progressed from NDBE to either HGD or EAC. There were eight progressors who had biopsy specimens with adequate DNA for analysis. The progressor and non-progressor cohort had similar demographic information and medical history. The progressor group trended towards being older at diagnosis (72 ± 10 vs. 64 ± 13 years, p = 0.097) and fewer progressors reported reflux symptoms (50 vs. 94.7%, p < 0.001). Progressor specimens had more overall CNAs (75% vs. 33.6%, p = 0.026). On univariable analysis, there was an association between progression and absence of GERD symptoms (OR 16.54 [3.42-80.03], p = 0.001), any CNA (OR 5.10 [1.18-23.30], p = 0.035), and CNA in GATA6 or ERBB2 (OR 6.72 [1.18-38.22], p = 0.032).
CONCLUSIONS: Patients who progressed from NDBE to HGD or EAC were older at first diagnosis of BE and fewer of the progressors reported symptoms of reflux when compared to non-progressors. Progression was associated with the presence of any CNA and specific CNAs in GATA6 or ERBB2.

Entities:  

Keywords:  Barrett’s esophagus; Esophageal adenocarcinoma; Progression; Somatic copy number alterations

Year:  2020        PMID: 32749611     DOI: 10.1007/s00464-020-07859-z

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  15 in total

1.  Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.

Authors:  Elizabeth L Bird-Lieberman; Jason M Dunn; Helen G Coleman; Pierre Lao-Sirieix; Dahmane Oukrif; Christina E Moore; Sibu Varghese; Brian T Johnston; Kenneth Arthur; Damian T McManus; Marco R Novelli; Maria O'Donovan; Christopher R Cardwell; Laurence B Lovat; Liam J Murray; Rebecca C Fitzgerald
Journal:  Gastroenterology       Date:  2012-07-03       Impact factor: 22.682

2.  Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.

Authors:  Lucas C Duits; Myrtle J van der Wel; Cary C Cotton; K Nadine Phoa; Fiebo J W Ten Kate; Cees A Seldenrijk; G Johan A Offerhaus; Mike Visser; Sybren L Meijer; Rosalie C Mallant-Hent; Kausilia K Krishnadath; Roos E Pouw; Jan G P Tijssen; Nicholas J Shaheen; Jacques J G H M Bergman
Journal:  Gastroenterology       Date:  2016-12-22       Impact factor: 22.682

3.  Genetic variants in Barrett's esophagus and esophageal adenocarcinoma: a literature review.

Authors:  Zachary M Callahan; Zhuqing Shi; Bailey Su; Jianfeng Xu; Michael Ujiki
Journal:  Dis Esophagus       Date:  2019-08-01       Impact factor: 3.429

4.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Authors:  B J Reid; L J Prevo; P C Galipeau; C A Sanchez; G Longton; D S Levine; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

5.  Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus.

Authors:  Louisa G Gordon; George C Mayne; Nicholas G Hirst; Timothy Bright; David C Whiteman; David I Watson
Journal:  Gastrointest Endosc       Date:  2013-09-27       Impact factor: 9.427

6.  Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.

Authors:  Sachin Wani; Gary Falk; Matthew Hall; Srinivas Gaddam; Amy Wang; Neil Gupta; Mandeep Singh; Vikas Singh; Keng-Yu Chuang; Vikram Boolchand; Hemanth Gavini; John Kuczynski; Priti Sud; Savio Reddymasu; Ajay Bansal; Amit Rastogi; Sharad C Mathur; Patrick Young; Brooks Cash; David A Lieberman; Richard E Sampliner; Prateek Sharma
Journal:  Clin Gastroenterol Hepatol       Date:  2010-11-27       Impact factor: 11.382

7.  Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.

Authors:  Austin M Dulak; Steven E Schumacher; Jasper van Lieshout; Yu Imamura; Cameron Fox; Byoungyong Shim; Alex H Ramos; Gordon Saksena; Sylvan C Baca; Jose Baselga; Josep Tabernero; Jordi Barretina; Peter C Enzinger; Giovanni Corso; Franco Roviello; Lin Lin; Santhoshi Bandla; James D Luketich; Arjun Pennathur; Matthew Meyerson; Shuji Ogino; Ramesh A Shivdasani; David G Beer; Tony E Godfrey; Rameen Beroukhim; Adam J Bass
Journal:  Cancer Res       Date:  2012-07-02       Impact factor: 12.701

8.  Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.

Authors:  Rajeswari Anaparthy; Srinivas Gaddam; Vijay Kanakadandi; Benjamin R Alsop; Neil Gupta; April D Higbee; Sachin B Wani; Mandeep Singh; Amit Rastogi; Ajay Bansal; Brooks D Cash; Patrick E Young; David A Lieberman; Gary W Falk; John J Vargo; Prashanti Thota; Richard E Sampliner; Prateek Sharma
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-22       Impact factor: 11.382

9.  Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.

Authors:  Jamie M J Weaver; Caryn S Ross-Innes; Nicholas Shannon; Andy G Lynch; Tim Forshew; Mariagnese Barbera; Muhammed Murtaza; Chin-Ann J Ong; Pierre Lao-Sirieix; Mark J Dunning; Laura Smith; Mike L Smith; Charlotte L Anderson; Benilton Carvalho; Maria O'Donovan; Timothy J Underwood; Andrew P May; Nicola Grehan; Richard Hardwick; Jim Davies; Arusha Oloumi; Sam Aparicio; Carlos Caldas; Matthew D Eldridge; Paul A W Edwards; Nitzan Rosenfeld; Simon Tavaré; Rebecca C Fitzgerald
Journal:  Nat Genet       Date:  2014-06-22       Impact factor: 38.330

10.  The landscape of somatic copy-number alteration across human cancers.

Authors:  Rameen Beroukhim; Craig H Mermel; Dale Porter; Guo Wei; Soumya Raychaudhuri; Jerry Donovan; Jordi Barretina; Jesse S Boehm; Jennifer Dobson; Mitsuyoshi Urashima; Kevin T Mc Henry; Reid M Pinchback; Azra H Ligon; Yoon-Jae Cho; Leila Haery; Heidi Greulich; Michael Reich; Wendy Winckler; Michael S Lawrence; Barbara A Weir; Kumiko E Tanaka; Derek Y Chiang; Adam J Bass; Alice Loo; Carter Hoffman; John Prensner; Ted Liefeld; Qing Gao; Derek Yecies; Sabina Signoretti; Elizabeth Maher; Frederic J Kaye; Hidefumi Sasaki; Joel E Tepper; Jonathan A Fletcher; Josep Tabernero; José Baselga; Ming-Sound Tsao; Francesca Demichelis; Mark A Rubin; Pasi A Janne; Mark J Daly; Carmelo Nucera; Ross L Levine; Benjamin L Ebert; Stacey Gabriel; Anil K Rustgi; Cristina R Antonescu; Marc Ladanyi; Anthony Letai; Levi A Garraway; Massimo Loda; David G Beer; Lawrence D True; Aikou Okamoto; Scott L Pomeroy; Samuel Singer; Todd R Golub; Eric S Lander; Gad Getz; William R Sellers; Matthew Meyerson
Journal:  Nature       Date:  2010-02-18       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.